Foshan Ionova Biotherapeutics Co. Ltd. has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin-protein ligase binding moiety covalently linked to an androgen receptor variant 7 (AR-v7) targeting moiety acting as AR-v7 degradation inducers reported to be useful for the treatment of prostate cancer.
K36 Therapeutics Inc. has obtained IND clearance from the U.S. FDA for KTX-2001, a selective, oral, small-molecule inhibitor of nuclear receptor-binding SET domain protein 2 (NSD2), a histone methyltransferase and oncogene that activates gene expression in some cancers.
Bio-Techne Corp. plans to sell its Exosome Diagnostics Inc. business to Mdxhealth SA for $15 million plus royalty payments, a steep cut from the $250 million the company paid to acquire Exodx in 2018. Mdxhealth estimates the unit will generate $20 million in revenue in 2026.
Radiopharma Clarity Pharmaceuticals Ltd. raised AU$203 million (US$132.22 million) in an institutional placement on Australia’s Securities Exchange to advance its late-stage pipeline of copper-based radiopharmaceuticals.
Nuclidium AG is poised to circumvent the complex production and supply issues that have held back access to radiopharmaceuticals after closing a CHF79 million (US$99.3 million) series B, to advance the clinical development of its copper isotopes and extend the global manufacturing network.
Prostate cancer is one of the most common male-related cancers, and understanding the underlying mechanisms is crucial for developing new treatment strategies and avoiding resistance development.
Nuclidium AG is poised to circumvent the complex production and supply issues that have held back access to radiopharmaceuticals after closing a CHF79 million (US$99.3 million) series B, to advance the clinical development of its copper isotopes and extend the global manufacturing network.
Innocare Pharma Ltd. has obtained IND approval from China’s National Medical Products Administration (NMPA) to initiate a clinical trial of the B7-H3 targeted antibody-drug conjugate.
Vitsgen Therapeutics Inc. recently provided details on the preclinical characterization of a new prostate-specific membrane antigen (PSMA)-targeted radiotheranostic agent, [177Lu]PSMA-VG-01, for the treatment of metastatic castration-resistant prostate cancer.
Actinium Pharmaceuticals Inc. recently presented data on ATNM-400, a new antibody radioconjugate that uses actinium-225 (Ac-225) to target a non-prostate-specific member antigen (PSMA) protein that is frequently overexpressed in several tumor types, including prostate cancer.
